I remain extremely bullish due to robust fundamentals, strong AI tailwinds, and compelling upside potential. The company posted a solid Q1 with 20% YoY revenue growth and EPS rising from $0.86 to $1.20, driven by AI-driven data center demand. Valuation scenarios suggest a 38% to 18% upside potential, with a target price of $133, supported by a conservative 10% revenue CAGR assumption.

Jim Wyckoff has spent over 25 years involved with the stock, financial and commodity markets. He was a financial journalist with the FWN newswire service for many years, including stints as a reporter on the rough-and-tumble commodity futures trading floors in Chicago and New York.

As of the May 7 close, the Technology Select Sector SPDR Fund NYSEARCA: XLK has provided a total return of approximately -8% on the year. Meanwhile, Monolithic has a total return of approximately +8%.

NEW YORK, NY / ACCESS Newswire / May 9, 2025 / If you suffered a loss on your Canopy Growth Corporation (NASDAQ:CGC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/canopy-growth-corporation-lawsuit-submission-form?prid=147705&wire=1 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / May 9, 2025 / If you suffered a loss on your Zenas BioPharma, Inc. (NASDAQ:ZBIO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/zenas-biopharma-inc-lawsuit-submission-form?prid=147697&wire=1 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / May 9, 2025 / If you suffered a loss on your TFI International Inc. (NYSE:TFII) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/tfi-international-inc-lawsuit-submission-form?prid=147698&wire=1 or contact Joseph E. Levi, Esq.

Management to host conference call at 8:30 AM ET, Friday, May 9, 2025 Management to host conference call at 8:30 AM ET, Friday, May 9, 2025

NEW YORK, NY / ACCESS Newswire / May 9, 2025 / If you suffered a loss on your Viatris Inc. (NASDAQ:VTRS) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/viatris-inc-lawsuit-submission-form-2?prid=147699&wire=1 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / May 9, 2025 / If you suffered a loss on your SoundHound AI, Inc. (NASDAQ:SOUN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/soundhound-ai-inc-lawsuit-submission-form?prid=147700&wire=1 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / May 9, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Agilysys, Inc. ("Agilysys, Inc.") (NASDAQ:AGYS) concerning possible violations of federal securities laws. On January 21, 2025, after the market closed, Agilysys issued a press release announcing third quarter revenue below expectations and the company's own guidance, resulting in a significant revision to Agilysys' FY25 revenue guidance.

NEW YORK, NY / ACCESS Newswire / May 9, 2025 / If you suffered a loss on your Open Lending Corporation (NASDAQ:LPRO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/open-lending-corporation-lawsuit-submission-form?prid=147702&wire=1 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / May 9, 2025 / If you suffered a loss on your Zynex, Inc. (NASDAQ:ZYXI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/zynex-inc-lawsuit-submission-form?prid=147703&wire=1 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / May 9, 2025 / If you suffered a loss on your Geron Corporation (NASDAQ:GERN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/geron-corporation-lawsuit-submission-form?prid=147704&wire=1 or contact Joseph E. Levi, Esq.

Jim Wyckoff has spent over 25 years involved with the stock, financial and commodity markets. He was a financial journalist with the FWN newswire service for many years, including stints as a reporter on the rough-and-tumble commodity futures trading floors in Chicago and New York.

CBNA, FMS, BNTGY, WYY and BCRX have been added to the Zacks Rank #1 (Strong Buy) List on May 9, 2025.

Docebo Inc. (DCBO) came out with quarterly earnings of $0.27 per share, beating the Zacks Consensus Estimate of $0.21 per share. This compares to earnings of $0.23 per share a year ago.

VANCOUVER, BC , May 9, 2025 /PRNewswire/ - International Tower Hill Mines Ltd. (the "Company") - (TSX: ITH) (NYSE American: THM) today announced that it has filed its unaudited first quarter Financial Statements and associated Management Discussion and Analysis and Quarterly Report on Form 10-Q for the three-month period ended March 31, 2025.

Shell's potential acquisition of BP could offer substantial synergies and shareholder returns, though it's not confirmed yet. Shell's strong financials include $4.8 billion in quarterly income, manageable $41 billion net debt, and robust FCF and capital investments. Shell's diversified portfolio, especially in LNG, supports strong segment performance and profitable CFFO, even in a weak oil price environment.

66% of patients with scalp psoriasis and 77% with genital psoriasis treated with investigational icotrokinra achieved site-specific clear or almost clear skin at Week 16 Icotrokinra continues to demonstrate a standout combination of significant skin clearance (IGA 0/1) and a favorable safety profile in a once daily pill SPRING HOUSE, Pa. , May 9, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced new data from the Phase 3 ICONIC-TOTALa study investigating icotrokinra (JNJ-2113), the first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor.

Shares of argenx declined yesterday as Vyvgart missed investors' expectations. Vyvgart saw the usual negative seasonal headwinds in the U.S. in the first quarter that were further exacerbated by the Medicare redesign. Underlying demand was strong across the globe, and Vyvgart looks well positioned for continued growth, which should be helped by the approval of the PFS and international indication expansion.